Opendata, web and dolomites

NIRCOThera SIGNED

Spatiotemporal, near-infrared light controlled carbon monoxide delivery for cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NIRCOThera project word cloud

Explore the words cloud of the NIRCOThera project. It provides you a very rough idea of what is the project "NIRCOThera" about.

release    microenvironment    cells    manner    precision    reactive    plan    clearance    conjugate    eradicate    protein    inflammatory    herein    ready    expression    combine    vivo    ros    disorders    infrared    human    generation       species    sites    walled    site    infiltrating    monoxide    impart    chemotherapeutics    fast    anti    therapeutic    chemotherapy    health    stability    modulatory    spatiotemporal    ultrahigh    oxygen    platform    rhenium    co    toxicity    strategy    loaded    naturally    biocompatibility    gaseous    progression    molecule    tissues    activation       models    tumours    angiogenesis    immune    releasing    cardiovascular    exogeneous    consists    shown    light    diseases    time    body    cancer    nanotubes    expecting    single    animal    components    dose    largely    relatively    treatment    functionalized    immunomodulatory    corms    profile    genes    intratumoural    exposure    exclusively    reported    purpose    nir    tumour    progress    near    rebr3    metastasis    molecules    avenue    triggered    multiple    inflammation    excretion    signaling    swcnts    bifunctional    net4    unexploited    realize    carbon    manipulate    lipid    chosen    critical    effect    followed    dependent    precise    sensitivity    cell   

Project "NIRCOThera" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

Carbon monoxide (CO) is a gaseous signaling molecule naturally produced by the human body. In recent years, CO has shown its anti-inflammatory and immunomodulatory properties and thus therapeutic potential in the treatment of inflammatory disorders and cardiovascular diseases. It is promising to exploit the modulatory effect of exogeneous CO in tumour microenvironment where inflammation and angiogenesis are the critical components of tumour progression and metastasis, which is largely unexploited. For this purpose, it is key to manipulate CO exposure in a precise dose and time-controlled manner exclusively at the tumour site. Herein, we propose to develop a new CO delivery avenue, enabling controlled CO release to tumour sites with spatiotemporal precision by using near infrared light (NIR). Specifically, the strategy consists of single-walled carbon nanotubes (SWCNTs) loaded with CO releasing molecules (CORMs). We have reported the development of a SWCNTs-based bifunctional system that enables intratumoural protein delivery and NIR activation, which is ready to be applied to realize controlled CO release in vivo. We plan to conjugate [ReBr3(CO)3][NEt4]2 to SWCNTs. The rhenium complex is chosen because of its stability and non-toxicity while the lipid functionalized SWCNTs have shown biocompatibility, ultrahigh tumour uptake and relatively fast clearance and excretion from the health tissues, which impart the platform promising for in vivo application. We will evaluate the stability of the platform, followed by the NIR-triggered CO release profile and then dose- and time-dependent effect on both cancer cells and tumour-infiltrating immune cells, including the generation of reactive oxygen species (ROS) and expression of multiple genes associated with tumour progress. Furthermore, expecting increased cancer cell sensitivity to chemotherapeutics with CO treatment, we will combine the proposed strategy with current chemotherapy to eradicate tumours in animal models.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NIRCOTHERA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NIRCOTHERA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

VINCI (2020)

The Value of Information and Choice to Improve Control.

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More  

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More